Massimo Origoni

Proposal of a Risk Stratification Model for Recurrence After Excisional Treatment of High-Grade Cervical Intraepithelial Neoplasia (HG-CIN).

Journal: Diagnostics (Basel, Switzerland)

Published: May 05, 2025

Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment-Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.

Journal: Cancers

Published: February 13, 2024

HPV Opportunistic Vaccination: A Literature Review and a Single-Center Experience in Northern Italy through the COVID-19 Pandemic.

Journal: Vaccines

Published: July 21, 2023

Colposcopy Accuracy and Diagnostic Performance: A Quality Control and Quality Assurance Survey in Italian Tertiary-Level Teaching and Academic Institutions-The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).

Journal: Diagnostics (Basel, Switzerland)

Published: May 05, 2023

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group).

Journal: Cancers

Published: April 11, 2023

Botulinum toxin injection in vulva and vagina. Evidence from a literature systematic review.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: December 29, 2022

Monitoring the activities of Italian colposcopy clinics before and during the COVID-19 pandemic.

Journal: Journal of gynecologic oncology

Published: April 01, 2022

Hysterectomy for cervical intraepithelial neoplasia: A retrospective observational multi-institutional study.

Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Published: January 16, 2022

Prognostic Significance of Neutrophil/Lymphocytes Ratio (NLR) in Predicting Recurrence of Cervical Dysplasia.

Journal: BioMed research international

Published: October 10, 2021

Low-Malignant Schwannoma of the Cervix in Pregnancy: A Case Report and Literature Systematic Review.

Journal: Case reports in obstetrics and gynecology

Published: July 30, 2021

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Journal: Vaccine

Published: October 01, 2020

Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 17, 2020

Proposal of a Risk Stratification Model for Recurrence After Excisional Treatment of High-Grade Cervical Intraepithelial Neoplasia (HG-CIN).

Proposal of a Risk Stratification Model for Recurrence After Excisional Treatment of High-Grade Cervical Intraepithelial Neoplasia (HG-CIN).

Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment-Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.

Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment-Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.

HPV Opportunistic Vaccination: A Literature Review and a Single-Center Experience in Northern Italy through the COVID-19 Pandemic.

HPV Opportunistic Vaccination: A Literature Review and a Single-Center Experience in Northern Italy through the COVID-19 Pandemic.

Colposcopy Accuracy and Diagnostic Performance: A Quality Control and Quality Assurance Survey in Italian Tertiary-Level Teaching and Academic Institutions-The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).

Colposcopy Accuracy and Diagnostic Performance: A Quality Control and Quality Assurance Survey in Italian Tertiary-Level Teaching and Academic Institutions-The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group).

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group).

Botulinum toxin injection in vulva and vagina. Evidence from a literature systematic review.

Botulinum toxin injection in vulva and vagina. Evidence from a literature systematic review.

Monitoring the activities of Italian colposcopy clinics before and during the COVID-19 pandemic.

Monitoring the activities of Italian colposcopy clinics before and during the COVID-19 pandemic.

Hysterectomy for cervical intraepithelial neoplasia: A retrospective observational multi-institutional study.

Hysterectomy for cervical intraepithelial neoplasia: A retrospective observational multi-institutional study.

Prognostic Significance of Neutrophil/Lymphocytes Ratio (NLR) in Predicting Recurrence of Cervical Dysplasia.

Prognostic Significance of Neutrophil/Lymphocytes Ratio (NLR) in Predicting Recurrence of Cervical Dysplasia.

Low-Malignant Schwannoma of the Cervix in Pregnancy: A Case Report and Literature Systematic Review.

Low-Malignant Schwannoma of the Cervix in Pregnancy: A Case Report and Literature Systematic Review.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.

Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.